+

WO2003041655A3 - Therapeutic agent composition and method of use - Google Patents

Therapeutic agent composition and method of use Download PDF

Info

Publication number
WO2003041655A3
WO2003041655A3 PCT/US2002/036639 US0236639W WO03041655A3 WO 2003041655 A3 WO2003041655 A3 WO 2003041655A3 US 0236639 W US0236639 W US 0236639W WO 03041655 A3 WO03041655 A3 WO 03041655A3
Authority
WO
WIPO (PCT)
Prior art keywords
cerebral
disease
prevention
cyclic
therapeutic agent
Prior art date
Application number
PCT/US2002/036639
Other languages
French (fr)
Other versions
WO2003041655A2 (en
Inventor
Loi Tran
Original Assignee
Loi Tran
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loi Tran filed Critical Loi Tran
Priority to AU2002363800A priority Critical patent/AU2002363800A1/en
Priority to CA2466701A priority patent/CA2466701C/en
Publication of WO2003041655A2 publication Critical patent/WO2003041655A2/en
Publication of WO2003041655A3 publication Critical patent/WO2003041655A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention also relates to the use of cyclic Prolyl Glycine ('cyclic PG' or 'cPG') and analoges and mimetics thereof, as neuroprotective agents for the tratement and or prevention of neurological disorders including but not limited ot cerebral ischemia or cerebral infaction resulting from a range of phenomena, such as thromboembolic or hemorrhagic stroke, cerebral basospasms, hypoglycemia, cardic arrest, status epilepticus, perinatal asphyxia, anoxia sah as from drowning, pulmonary surger, and cerebral trauma, as well as to the treatment and prevention of chronic neurodenenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, and as anticonvulsants.
PCT/US2002/036639 2001-11-13 2002-11-12 Therapeutic agent composition and method of use WO2003041655A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002363800A AU2002363800A1 (en) 2001-11-13 2002-11-12 Therapeutic agent composition and method of use
CA2466701A CA2466701C (en) 2001-11-13 2002-11-12 Neuroprotective use of cyclic prolyl glycine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NZ515432 2001-11-13
NZ51543201 2001-11-13
US40590902P 2002-08-26 2002-08-26
US60/405,909 2002-08-26

Publications (2)

Publication Number Publication Date
WO2003041655A2 WO2003041655A2 (en) 2003-05-22
WO2003041655A3 true WO2003041655A3 (en) 2004-09-10

Family

ID=26652293

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/036639 WO2003041655A2 (en) 2001-11-13 2002-11-12 Therapeutic agent composition and method of use

Country Status (3)

Country Link
AU (1) AU2002363800A1 (en)
CA (1) CA2466701C (en)
WO (1) WO2003041655A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232798B2 (en) 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
AUPS255202A0 (en) * 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with motor neuron degeneration
US8791117B2 (en) 2003-09-03 2014-07-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
PL1664050T3 (en) 2003-09-03 2016-08-31 Neuren Pharmaceuticals Ltd Neuroprotective bicyclic compounds and pharmaceutical compositions containing them
RU2355413C1 (en) * 2007-12-06 2009-05-20 Закрытое Акционерное Общество "Биоген Технолоджиз" Pharmaceutical preparation for treating demyelinating diseases of nervous system, preparation favouring recovery of myelin sheath of nerve fibre, and method of treating demyelinating diseases of nervous system
EP2338492A1 (en) * 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
US10842849B2 (en) 2011-02-28 2020-11-24 The Schepens Eye Research Institute, Inc. Methods for promoting neuronal outgrowth by insulin-like growth factor binding protein-like 1 (IGFBPL-1) in glaucoma or leber's optic neuropathy
CN112423774A (en) * 2018-05-15 2021-02-26 L·H·L·特兰 Therapeutic compositions and methods of use for treating mild cognitive impairment, depression and psychological disorders

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251865B1 (en) * 1997-04-04 2001-06-26 Genentech, Inc. Insulin-like growth factor agonist molecules
US6258582B1 (en) * 1998-09-30 2001-07-10 Millennium Pharmaceuticals, Inc. CSAPTP nucleic acid molecules and uses therefor
US6284778B1 (en) * 1996-11-13 2001-09-04 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US6291213B1 (en) * 1996-11-14 2001-09-18 The Trustees Of Columbia University In The City Of New York Method for generating a directed, recombinant fusion nucleic acid
US6291511B1 (en) * 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
US6303576B1 (en) * 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284778B1 (en) * 1996-11-13 2001-09-04 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US6291213B1 (en) * 1996-11-14 2001-09-18 The Trustees Of Columbia University In The City Of New York Method for generating a directed, recombinant fusion nucleic acid
US6251865B1 (en) * 1997-04-04 2001-06-26 Genentech, Inc. Insulin-like growth factor agonist molecules
US6291511B1 (en) * 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
US6258582B1 (en) * 1998-09-30 2001-07-10 Millennium Pharmaceuticals, Inc. CSAPTP nucleic acid molecules and uses therefor
US6303576B1 (en) * 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression

Also Published As

Publication number Publication date
WO2003041655A2 (en) 2003-05-22
CA2466701A1 (en) 2003-05-22
AU2002363800A1 (en) 2003-05-26
CA2466701C (en) 2013-11-12

Similar Documents

Publication Publication Date Title
DE69937198D1 (en) TREATMENT OF ALZHEIMER DISEASE BY INCREASING THE CYTIDINE MIRROR IN VIVO
WO2008011476A3 (en) Compositions and methods for modulating sirtuin activity
WO2002080850A3 (en) Bulking agents as satiety agents
WO2002100347A3 (en) Prodrugs of gaba analogs, compositions and uses thereof
WO2006105403A3 (en) Treatment of eye disorders with sirtuin modulators
NO20060328L (en) Combination of mGluR2 antagonist and ACHE inhibitor for the treatment of acute and / or chronic neurological disorders
WO2006127987A3 (en) Treatment of eye disorders with sirtuin modulators
UA94034C2 (en) Rapamcyin analogues and the uses thereof in the treatment of neurologial proliferative and inflammatory disorders
WO2005039504A3 (en) Compounds and methods for treating toll-like receptor 2-related diseases and conditions
WO2000006085A3 (en) Compounds and methods
WO2002088101A3 (en) Inhibitors of bace
SI1525177T1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof
EP1463530A4 (en) Adeno-associated virus-mediated delivery of gdnf to skeletal muscles
GB0108592D0 (en) Therapeutic agents
WO2006121560A8 (en) Methods and compositions for treatment of cns disorders
ES2318119T3 (en) PROCEDURE AND COMPOSITIONS TO ALTER THE PROFILE OF THE EDUCATING EFFECT OF LA SUCRALOSA.
WO2002094228A8 (en) Prevention and treatment of allergies by helminthic regulation of ige
WO2007067511A3 (en) Morpholine carboxamide prokineticin receptor antagonists
WO2003041655A3 (en) Therapeutic agent composition and method of use
WO2002038797A3 (en) Modulators of bruton's tyrosine kinase, their identification and use
WO2003011274A3 (en) Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma
WO2003103662A3 (en) Inhibitors of glycoprotein vi
WO2002003972A3 (en) Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
WO2001053457A3 (en) Vaccines against neurodegenerative disorders
WO2002011712A3 (en) Combination of huperzine and nicotinic compounds as a neuroprotective agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2466701

Country of ref document: CA

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载